A61K 2039/5156
Expressing foreign proteins
Official title: {expressing foreign proteins}
A61K2039/5156 (Expressing foreign proteins) appears on 536 US grants and 915 published applications in this corpus.
Search patents in A61K- Granted patents
- 536
- Published applications
- 915
- Assignees
- 423
- Inventors
- 1,621
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 12 | 0 |
| 2000 | 7 | 0 |
| 2001 | 11 | 1 |
| 2002 | 12 | 33 |
| 2003 | 16 | 26 |
| 2004 | 8 | 34 |
| 2005 | 11 | 28 |
| 2006 | 7 | 14 |
| 2007 | 9 | 19 |
| 2008 | 15 | 19 |
| 2009 | 11 | 23 |
| 2010 | 14 | 18 |
| 2011 | 10 | 26 |
| 2012 | 17 | 18 |
| 2013 | 11 | 20 |
| 2014 | 8 | 5 |
| 2015 | 11 | 16 |
| 2016 | 10 | 19 |
| 2017 | 18 | 33 |
| 2018 | 14 | 41 |
| 2019 | 24 | 44 |
| 2020 | 36 | 59 |
| 2021 | 47 | 80 |
| 2022 | 38 | 83 |
| 2023 | 32 | 75 |
| 2024 | 51 | 88 |
| 2025 | 34 | 63 |
| 2026 | 27 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy9 Jun 2026US 12,648,962 B2Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Ionizable lipids for nucleic acid delivery17 Sep 2026US 2026/0273066 A1Global Life Sciences Solutions Canada ULC
- Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof10 Sep 2026US 2026/0263558 A1Regeneron Pharmaceuticals, Inc.
- Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof10 Sep 2026US 2026/0265380 A1Institute for Research in Biomedicine
Most cited
By later US patents
- Methods of cell culture for adoptive cell therapy156US 8,956,860 B22015
- Anti-CD40 monoclonal antibodies capable of blocking B-cell activation109US 5,677,165 AChiron Corporation · 1997
- AAV2 vectors and methods109US 6,962,815 B2Children's Hopital Inc. · 2005
- Binding domain-immunoglobulin fusion proteins96US 7,754,208 B2Trubion Pharmaceuticals, Inc. · 2010
- Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same90US 5,891,432 AThe Immune Response Corporation · 1999